Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes

E.L. Giraud,K. Westerdijk,M.B.A. van der Kleij,N.A.D. Guchelaar,M. Meertens,R.F. Bleckman,A. Rieborn,M. Mohammadi,E. Roets,R.H.J. Mathijssen,A.D.R. Huitema,S.L.W. Koolen,H. Gelderblom,D.J.A.R. Moes,A.K.L. Reyners,D.J. Touw,P. Keizer-Heldens,A.W. Oosten,W.T.A. van der Graaf,N. Steeghs,N.P. van Erp,I.M.E. Desar
DOI: https://doi.org/10.1016/j.esmoop.2024.103477
IF: 6.883
2024-06-05
ESMO Open
Abstract:This study is the first to assess the benefits of TDM of sunitinib in patients with GIST regarding efficacy and toxicity. Patients who experienced DLTs had significantly longer mPFS compared to those who did not. TDM should be used as a tool within the broader context of a patients' comprehensive clinical picture. Sunitinib is an oral anticancer drug approved for the treatment of among others gastrointestinal stromal tumor (GIST). Previous analyses demonstrated an exposure–response relationship at the standard dose, and minimum target levels of drug exposure have been defined above which better treatment outcomes are observed. Therapeutic drug monitoring (TDM) could be used as a tool to optimize the individual dose, aiming at sunitinib trough concentrations ≥37.5 ng/ml for continuous dosing. Nonetheless, data on the added value of TDM-guided dosing on clinical endpoints are currently lacking. Therefore, we evaluate the effect of TDM in patients with advanced and metastatic GIST treated with sunitinib in terms of efficacy and toxicity. A TDM-guided cohort was compared to a non-TDM-guided cohort in terms of median progression-free survival (mPFS) and overall survival (mOS). Also, mPFS between patients with and without dose-limiting toxicities (DLTs) was compared. Patients in the prospective cohort were included in two studies on TDM-guided dosing (the DPOG-TDM study and TUNE study). The retrospective cohort consisted of patients from the Dutch GIST Registry who did not receive TDM-guided dosing. In total, 51 and 106 patients were included in the TDM-guided cohort and non-TDM-guided cohort, respectively. No statistical difference in mPFS was observed between these two cohorts (39.4 versus 46.9 weeks, respectively; P = 0.52). Patients who experienced sunitinib-induced DLTs had longer mPFS compared to those who did not (51.9 versus 28.9 weeks, respectively; P = 0.002). Our results do not support the routine use of TDM-guided dose optimization of sunitinib in patients with advanced/metastatic GIST to improve survival.
oncology
What problem does this paper attempt to address?